Longboard Pharmaceuticals Inc Funding & Investors
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
longboardpharma.comTotal Amount Raised: $1,596,968
Longboard Pharmaceuticals Inc Funding Rounds
Post Ipo Equity
$1,072,300
Post Ipo Debt
$350,000
Post Ipo Debt
$174,668
IPO
Unknown
Funding info provided by Diffbot.